- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01451346
Study in Patients With Mild to Moderate Psoriasis (AH-PSR-01)
B.Infantis 35624 in Patients With Mild to Moderate Chronic Plaque Psoriasis -a Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland
- Alimentary Health Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects diagnosed with mild to moderate psoriasis as defined by the clinician,
- Has a Psoriasis Area and Severity Index{PASI} of less than 20,
- Male or female subjects,
- Aged between 18-60 years of age,
- Non-pregnant female and must agree to use adequate method of contraception during the study,
- Is capable of giving written informed consent prior to study entry,
- Be willing to refrain from taking dietary supplements or other foods that contain fermented live bacteria within 1 month prior to treatment and during the study,
- Have not participated in a clinical drug study or used an investigational new drug during the past previous 30 days,
- Clinical Chemistry and haematology results from Visit 1 are within normal limits,
- Be willing to refrain from using any topical psoriactic cream 2 weeks prior to treatment and during the study.
Exclusion Criteria:
- Are less than 18 years of age, and not more than 60 years of age,
- History of sensitivity to lactose [eg, lactose intolerance] or other dairy products,
- History of consumption of probiotics,1 month prior to treatment,
- Being treated with steroids 2 weeks prior to entry, Diseases of the gastrointestinal tract,liver,pancreas and biliary tree[eg;gastritis,symptomatic gall stones,duodenal ulcer,gastroenteritis,diverticulitis.] Exceptions include haemorrhoids,hiatus hernia and asymptomatic gall stones.
- History of major gastric,hepatic,pancreatic or intestinal surgery or perforation,excluding cholescystectomy,appendicectomy,haemorrhoidectomy or polypectomy.
- Recent unexplained rectal bleeding and/or significant unexplained weight loss.
- Antibiotic use within one month prior to Visit 1. have a significant acute or chronic coexisting illness{cardiovascular,gastrointestinal,immunological}or a condition, which contraindicates,in the investigators judgement entry to the study.
- Patients with Diabetes Mellitus.
- Individuals who, in the opinion of the investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the trial.
- Subjects currently receiving treatment involving experimental drugs.
- If a subjects has been in a recent experimental trial,must be not less than 30 days prior to this study.
- Have a concomitant end stage organ disease eg; cardiovascular,hepatic,pulmonary,renal,which , in the Investigators judgement,contraindicates participation in the study.
- Have a history of malignancy in the past 5 years with the exception of Basal Cell Carcinoma.
- Evidence of alcohol or drug abuse.
- Evidence of unstable forms of psoriasis,including guttate, erthrodermic , exfoliative or pustular psoriasis.
- Evidence of other inflammatory skin disease that may confound the evaluation of psoriasis.
- Has had systematic antipsoriatic treatment or PUVA therapy within the previous 4 weeks.
- Subject who has had UVB therapy with the previous 2 weeks.
- If the subjects scores >20% on the PASI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo sachets contained 5 grams of Maltodextrin only.
|
One sachet daily for 12 weeks
|
Experimental: B Infantis 35624
Each 5gram freeze-dried powder contained ≥1*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
|
One sachet daily for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Psoriasis area and severity index between baseline and end of feeding
Time Frame: At 12 weeks
|
The PASI score stands for Psoriasis Area and Severity Index.
This tool allows researchers to put an objective number on what would otherwise be a very subjective idea: how bad is a person's psoriasis.
To make up the score, the three features of a psoriatic plaque (redness) scaling and thickness are each assigned a number from 0 to 4 with 4 being worst.
Then the extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72
|
At 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psoriasis Disability Index[PDI}
Time Frame: at 12 weeks
|
The Psoriasis Disability Index questionnaire is designed for use in adults, i.e. patients over the age of 16. It is self explanatory and can be handed to the patient who is asked to fill it in without the need for a detailed explanation. It is usually completed in three or four minutes. There are two possible alternative formats of the PDI. One uses visual analogue scales for each answer, the other uses tick box choices for each answer |
at 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Liam O Mahony, Dr., Alimentary Health Ltd
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Psoriasis Pilot Study
- AH-PSR-01 (Registry Identifier: Clinicaltrials.gov)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on B. Infantis 35624
-
Procter and GambleCompletedBloating | Abdominal DiscomfortUnited States
-
Procter and GambleAlimentary Health LtdCompletedIrritable Bowel SyndromeUnited Kingdom
-
University College CorkEuropean CommissionUnknown
-
Evolve BioSystems, Inc.University of California, DavisCompletedGut MicrobiomeUnited States
-
Evolve BioSystems, Inc.TerminatedInfantile ColicUnited States
-
University of California, DavisEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFecal Microflora in the Formula Fed Premature InfantUnited States
-
University of Cape TownEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingVaccine Reaction | Hiv | Microbial Colonization | Infant DevelopmentSouth Africa
-
Prolacta BioscienceRecruiting
-
University of California, DavisEvolve BioSystems, Inc.Withdrawn
-
Helmholtz Zentrum MünchenUniversitaire Ziekenhuizen KU Leuven; Technical University of Munich; Medical... and other collaboratorsRecruitingDiabetes Mellitus, Type 1Belgium, Germany, Poland, Sweden, United Kingdom